Which has higher valuation and earnings, IMDX or VOR?

Vor Biopharma has lower revenue, but higher earnings than Oncocyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncocyte $4.05M 45.13 -$50.22M -$1.48 N/A Vor Biopharma N/A N/A N/A N/A N/A

Is IMDX or VOR more profitable?

Vor Biopharma has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Company Net Margins Return on Equity Return on Assets Oncocyte -2,454.64% N/A -96.96% Vor Biopharma N/A N/A N/A

Which has stronger earnings and valuation, IMDX or IVA?

Oncocyte has higher earnings, but lower revenue than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncocyte $4.05M 45.13 -$50.22M -$1.48 N/A Inventiva $5.07M 165.10 -$400.67M N/A N/A

Is IMDX or IVA more profitable?

Inventiva has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Company Net Margins Return on Equity Return on Assets Oncocyte -2,454.64% N/A -96.96% Inventiva N/A N/A N/A

Oncocyte (IMDX) Competitors

$5.66 -0.29 (-4.87%)

As of 01:01 PM Eastern

Compare

IMDX vs. AURA, VOR, ANRO, IVA, and RLMD

Should you buy Oncocyte stock or one of its competitors? MarketBeat compares Oncocyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncocyte include Aura Biosciences (AURA), Vor Biopharma (VOR), Alto Neuroscience (ANRO), Inventiva (IVA), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry.

How does Oncocyte compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Oncocyte (NASDAQ:IMDX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 55.4% of Oncocyte shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by company insiders. Comparatively, 2.1% of Oncocyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aura Biosciences currently has a consensus price target of $20.50, suggesting a potential upside of 198.83%. Oncocyte has a consensus price target of $12.00, suggesting a potential upside of 112.01%. Given Aura Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Aura Biosciences is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Aura Biosciences had 1 more articles in the media than Oncocyte. MarketBeat recorded 3 mentions for Aura Biosciences and 2 mentions for Oncocyte. Oncocyte's average media sentiment score of 0.44 beat Aura Biosciences' score of 0.19 indicating that Oncocyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Aura Biosciences	Neutral
Oncocyte	Neutral

Aura Biosciences has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Oncocyte	-2,454.64%	N/A	-96.96%

Oncocyte has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Oncocyte	$4.05M	45.13	-$50.22M	-$1.48	N/A

Aura Biosciences has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Oncocyte has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

Summary

Aura Biosciences beats Oncocyte on 8 of the 15 factors compared between the two stocks.

How does Oncocyte compare to Vor Biopharma?

Oncocyte (NASDAQ:IMDX) and Vor Biopharma (NASDAQ:VOR) are both small-cap manufacturing companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Vor Biopharma had 1 more articles in the media than Oncocyte. MarketBeat recorded 3 mentions for Vor Biopharma and 2 mentions for Oncocyte. Vor Biopharma's average media sentiment score of 0.47 beat Oncocyte's score of 0.44 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncocyte	Neutral
Vor Biopharma	Neutral

Vor Biopharma has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
Vor Biopharma	N/A	N/A	N/A

Oncocyte presently has a consensus price target of $12.00, indicating a potential upside of 112.01%. Vor Biopharma has a consensus price target of $42.25, indicating a potential upside of 219.11%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Oncocyte has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market.

55.4% of Oncocyte shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 2.1% of Oncocyte shares are held by insiders. Comparatively, 0.3% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vor Biopharma has lower revenue, but higher earnings than Oncocyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	45.13	-$50.22M	-$1.48	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Summary

Vor Biopharma beats Oncocyte on 9 of the 12 factors compared between the two stocks.

How does Oncocyte compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Oncocyte (NASDAQ:IMDX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Oncocyte has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Oncocyte	$4.05M	45.13	-$50.22M	-$1.48	N/A

Alto Neuroscience currently has a consensus price target of $35.25, indicating a potential upside of 87.80%. Oncocyte has a consensus price target of $12.00, indicating a potential upside of 112.01%. Given Oncocyte's higher possible upside, analysts plainly believe Oncocyte is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Alto Neuroscience had 13 more articles in the media than Oncocyte. MarketBeat recorded 15 mentions for Alto Neuroscience and 2 mentions for Oncocyte. Oncocyte's average media sentiment score of 0.44 beat Alto Neuroscience's score of -0.61 indicating that Oncocyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Negative
Oncocyte	Neutral

Alto Neuroscience has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

Alto Neuroscience has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Oncocyte	-2,454.64%	N/A	-96.96%

55.4% of Oncocyte shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by company insiders. Comparatively, 2.1% of Oncocyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Oncocyte beats Alto Neuroscience on 9 of the 15 factors compared between the two stocks.

How does Oncocyte compare to Inventiva?

Oncocyte (NASDAQ:IMDX) and Inventiva (NASDAQ:IVA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

In the previous week, Inventiva had 3 more articles in the media than Oncocyte. MarketBeat recorded 5 mentions for Inventiva and 2 mentions for Oncocyte. Inventiva's average media sentiment score of 0.55 beat Oncocyte's score of 0.44 indicating that Inventiva is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncocyte	Neutral
Inventiva	Positive

Oncocyte has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Inventiva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Oncocyte has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	45.13	-$50.22M	-$1.48	N/A
Inventiva	$5.07M	165.10	-$400.67M	N/A	N/A

Inventiva has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
Inventiva	N/A	N/A	N/A

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 2.1% of Oncocyte shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Oncocyte currently has a consensus target price of $12.00, indicating a potential upside of 112.01%. Inventiva has a consensus target price of $16.56, indicating a potential upside of 310.81%. Given Inventiva's stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Summary

Inventiva beats Oncocyte on 11 of the 14 factors compared between the two stocks.

How does Oncocyte compare to Relmada Therapeutics?

Oncocyte (NASDAQ:IMDX) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Relmada Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Oncocyte has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Oncocyte presently has a consensus price target of $12.00, indicating a potential upside of 112.01%. Relmada Therapeutics has a consensus price target of $12.00, indicating a potential upside of 88.09%. Given Oncocyte's higher probable upside, equities analysts plainly believe Oncocyte is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Oncocyte has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	45.13	-$50.22M	-$1.48	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

In the previous week, Relmada Therapeutics had 1 more articles in the media than Oncocyte. MarketBeat recorded 3 mentions for Relmada Therapeutics and 2 mentions for Oncocyte. Relmada Therapeutics' average media sentiment score of 0.85 beat Oncocyte's score of 0.44 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncocyte	Neutral
Relmada Therapeutics	Positive

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 2.1% of Oncocyte shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Relmada Therapeutics beats Oncocyte on 9 of the 16 factors compared between the two stocks.

Get Oncocyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMDX vs. The Competition

Export

Metric	Oncocyte	In Vitro, In Vivo Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$182.76M	$1.07B	$4.28B	$12.40B
Dividend Yield	N/A	N/A	7.92%	5.29%
P/E Ratio	-3.82	N/A	21.84	24.16
Price / Sales	45.13	257.94	133.48	124.65
Price / Cash	N/A	677.89	56.86	57.88
Price / Book	-5.15	67.76	32.71	6.69
Net Income	-$50.22M	-$18.48M	$109.80M	$336.98M
7 Day Performance	-11.70%	4.95%	-0.07%	0.45%
1 Month Performance	35.41%	19.27%	4.02%	4.95%
1 Year Performance	N/A	-44.71%	16.29%	34.01%

Oncocyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMDX Oncocyte	2.872 of 5 stars	$5.66 -4.9%	$12.00 +112.0%	N/A	$182.76M	$4.05M	N/A	120	Short Interest Increase
AURA Aura Biosciences	2.9245 of 5 stars	$7.60 flat	$20.50 +169.7%	+12.0%	$785.74M	N/A	N/A	50
VOR Vor Biopharma	2.9584 of 5 stars	$14.33 flat	$42.25 +194.8%	N/A	$776.49M	N/A	N/A	140	Analyst Forecast
ANRO Alto Neuroscience	2.0138 of 5 stars	$21.22 0.0%	$35.25 +66.1%	+621.4%	$744.69M	N/A	N/A	N/A
IVA Inventiva	3.392 of 5 stars	$5.07 flat	$16.56 +226.5%	+20.6%	$739.97M	$5.07M	N/A	100	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMDX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncocyte (IMDX) Competitors

IMDX vs. AURA, VOR, ANRO, IVA, and RLMD

How does Oncocyte compare to Aura Biosciences?

Summary

How does Oncocyte compare to Vor Biopharma?

Summary

How does Oncocyte compare to Alto Neuroscience?

Summary

How does Oncocyte compare to Inventiva?

Summary

How does Oncocyte compare to Relmada Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX vs. The Competition

Oncocyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncocyte (IMDX) Competitors

IMDX vs. AURA, VOR, ANRO, IVA, and RLMD

How does Oncocyte compare to Aura Biosciences?

Do institutionals & insiders have more ownership in AURA or IMDX?

Do analysts prefer AURA or IMDX?

Does the media refer more to AURA or IMDX?

Is AURA or IMDX more profitable?

Which has higher earnings & valuation, AURA or IMDX?

Which has more risk and volatility, AURA or IMDX?

Summary

How does Oncocyte compare to Vor Biopharma?

Does the media favor IMDX or VOR?

Is IMDX or VOR more profitable?

Do analysts prefer IMDX or VOR?

Which has more risk & volatility, IMDX or VOR?

Do institutionals and insiders hold more shares of IMDX or VOR?

Which has higher valuation and earnings, IMDX or VOR?

Summary

How does Oncocyte compare to Alto Neuroscience?

Which has higher earnings and valuation, ANRO or IMDX?

Do analysts prefer ANRO or IMDX?

Does the media prefer ANRO or IMDX?

Which has more volatility and risk, ANRO or IMDX?

Is ANRO or IMDX more profitable?

Do insiders & institutionals believe in ANRO or IMDX?

Summary

How does Oncocyte compare to Inventiva?

Does the media favor IMDX or IVA?

Which has more risk and volatility, IMDX or IVA?

Which has stronger earnings and valuation, IMDX or IVA?

Is IMDX or IVA more profitable?

Do institutionals and insiders believe in IMDX or IVA?

Do analysts recommend IMDX or IVA?

Summary

How does Oncocyte compare to Relmada Therapeutics?

Is IMDX or RLMD more profitable?

Which has more volatility and risk, IMDX or RLMD?

Do analysts recommend IMDX or RLMD?

Which has better valuation and earnings, IMDX or RLMD?

Does the media favor IMDX or RLMD?

Do institutionals & insiders believe in IMDX or RLMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX vs. The Competition

Oncocyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools